Equity Profile

RMD

ResMed Inc.

Health CareHealth Care Equipment$27.6B

Aug6Thu

Pre-Earnings Brief

UpcomingQ4-2026After Close5:00 PM EDT

Company Snapshot

ResMed Inc. is a health care company that specializes in equipment related to sleep disorders, such as sleep apnea, and chronic obstructive pulmonary disease (COPD)....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and will help gauge how well ResMed is managing its expenses and generating income.

N/A

Revenue Growth

Revenue growth indicates the company's ability to expand its market presence and attract new customers, which is vital for long-term success.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

RMD Q4-2026 Earnings Preview

Context

Company Snapshot

ResMed Inc. is a health care company that specializes in equipment related to sleep disorders, such as sleep apnea, and chronic obstructive pulmonary disease (COPD). With a market cap of $30 billion, ResMed plays a crucial role in the health care equipment sector, especially as demand for respiratory care solutions continues to grow amid an aging population and increasing awareness of sleep health.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

100%

Avg EPS Surprise

+3.72%

Avg Stock Reaction

+0.21%

Last Quarter Recap

In the last quarter, ResMed reported an EPS of $2.86, surpassing expectations by 2.58%. However, revenue figures were not disclosed, leaving some uncertainty about overall performance.

Management Promises & Guidance

Continue to innovate in sleep and respiratory care technologies.
Focus on expanding market share in emerging markets.
Enhance customer engagement through digital health solutions.

Expectations

Wall Street Expectations

Overall, expectations for ResMed's upcoming earnings report are mixed, with investors looking for continued growth in EPS and revenue despite the lack of specific guidance.

Bull Case

If ResMed can maintain its track record of beating EPS estimates, it may signal strong operational efficiency and market demand, boosting investor confidence.

Bear Case

Conversely, if the company fails to provide clear guidance or shows signs of slowing growth, it could lead to a negative reaction from investors.

Expectations

Two Questions That Matter

The print will turn on these two things.

What is the expected EPS for this quarter, and how does it compare to previous quarters?

Given ResMed's consistent history of beating EPS estimates, this will be a critical measure of ongoing profitability and operational efficiency.

What insights can management provide regarding market share in the sleep apnea device segment?

Understanding market share dynamics will help investors assess ResMed's competitive position and growth potential in a key area of its business.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating ResMed's ability to capture market share in emerging markets, which could significantly boost revenue growth.

Supporting Evidence

ResMed has consistently beaten EPS estimates, indicating strong operational capabilities.

The options market is pricing a larger move than historical averages suggest, indicating potential for a surprise.

Management's focus on digital health solutions could drive new revenue streams that are not fully accounted for.

Key Risk

If ResMed's market share in sleep apnea devices shows unexpected growth, it could challenge current revenue projections.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance will be closely watched as it reflects ResMed's ability to sustain growth in a competitive health care equipment market.

Bull Confirmed If

An EPS of $2.90 or higher would confirm strong operational performance and market demand.

Bear Confirmed If

An EPS below $2.70 would raise concerns about profitability and market challenges.

Pre-Earnings Positioning

Options Market

Implied Move

±8.1%

Historical Avg

±0.9%

Pricing rich

The options market is pricing in an 8.1% potential move, indicating that traders expect significant volatility around the earnings announcement.

Options are pricing ±5.1% while RMD has averaged ±0.9% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.3%

30d HV

31.1%

Calls (4K)P/C Ratio: 0.65Puts (155K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If ResMed beats expectations, history suggests a positive reaction, with an average 1-day move of +0.21%, confirming strong operational performance.

In-Line / Cautious

If results are in line with expectations, the stock may experience muted movement as investors await further clarity on future growth.

Miss

A miss could lead to a decline, with historical patterns indicating an average 1-day move of -0.54%, reflecting disappointment in performance.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new product launches in sleep and respiratory care.
2Insights into customer engagement strategies and their effectiveness.
3Management's outlook on market conditions and competitive landscape.
4Details on international expansion efforts and performance in emerging markets.
5Any commentary on cost management and operational efficiencies.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Danaos Corporation

Company Snapshot

ResMed Inc. is a health care company that specializes in equipment related to sleep disorders, such as sleep apnea, and chronic obstructive pulmonary disease (COPD)....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and will help gauge how well ResMed is managing its expenses and generating income.

N/A

Revenue Growth

Revenue growth indicates the company's ability to expand its market presence and attract new customers, which is vital for long-term success.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

RMD Q4-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

100%

Avg EPS Surprise

+3.72%

Avg Stock Reaction

+0.21%

Last Quarter Recap

In the last quarter, ResMed reported an EPS of $2.86, surpassing expectations by 2.58%. However, revenue figures were not disclosed, leaving some uncertainty about overall performance.

Management Promises & Guidance

Continue to innovate in sleep and respiratory care technologies.
Focus on expanding market share in emerging markets.
Enhance customer engagement through digital health solutions.

Expectations

Wall Street Expectations

Overall, expectations for ResMed's upcoming earnings report are mixed, with investors looking for continued growth in EPS and revenue despite the lack of specific guidance.

Bull Case

If ResMed can maintain its track record of beating EPS estimates, it may signal strong operational efficiency and market demand, boosting investor confidence.

Bear Case

Conversely, if the company fails to provide clear guidance or shows signs of slowing growth, it could lead to a negative reaction from investors.

Expectations

Two Questions That Matter

The print will turn on these two things.

What is the expected EPS for this quarter, and how does it compare to previous quarters?

Given ResMed's consistent history of beating EPS estimates, this will be a critical measure of ongoing profitability and operational efficiency.

What insights can management provide regarding market share in the sleep apnea device segment?

Understanding market share dynamics will help investors assess ResMed's competitive position and growth potential in a key area of its business.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating ResMed's ability to capture market share in emerging markets, which could significantly boost revenue growth.

Supporting Evidence

ResMed has consistently beaten EPS estimates, indicating strong operational capabilities.

The options market is pricing a larger move than historical averages suggest, indicating potential for a surprise.

Management's focus on digital health solutions could drive new revenue streams that are not fully accounted for.

Key Risk

If ResMed's market share in sleep apnea devices shows unexpected growth, it could challenge current revenue projections.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance will be closely watched as it reflects ResMed's ability to sustain growth in a competitive health care equipment market.

Bull Confirmed If

An EPS of $2.90 or higher would confirm strong operational performance and market demand.

Bear Confirmed If

An EPS below $2.70 would raise concerns about profitability and market challenges.

Pre-Earnings Positioning

Options Market

Implied Move

±8.1%

Historical Avg

±0.9%

Pricing rich

The options market is pricing in an 8.1% potential move, indicating that traders expect significant volatility around the earnings announcement.

Options are pricing ±5.1% while RMD has averaged ±0.9% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.3%

30d HV

31.1%

Calls (4K)P/C Ratio: 0.65Puts (155K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If ResMed beats expectations, history suggests a positive reaction, with an average 1-day move of +0.21%, confirming strong operational performance.

In-Line / Cautious

If results are in line with expectations, the stock may experience muted movement as investors await further clarity on future growth.

Miss

A miss could lead to a decline, with historical patterns indicating an average 1-day move of -0.54%, reflecting disappointment in performance.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new product launches in sleep and respiratory care.
2Insights into customer engagement strategies and their effectiveness.
3Management's outlook on market conditions and competitive landscape.
4Details on international expansion efforts and performance in emerging markets.
5Any commentary on cost management and operational efficiencies.